🍾 Beverages
Miss
✦ AI
Kweichow Moutai posted +6.6% net revenue growth in Q1 2026 (RMB 53.9bn), recovering after a deliberate slowdown in 2H25 to stabilise wholesale prices. Morningstar: 'Steady Start to 2026 as Sales Reform Gains Traction'. The iMoutai direct channel (30% first-time buyers, 57% under 40) is rapidly gaining share. If Q2 2026 tracks similarly to Q1 (+6%), the H1 target of >5% is highly achievable. No direct Polymarket signal; Morningstar calibration and Q1 dynamics support 68%.
📈 Economy
Miss
✦ AI
At his debut FOMC meeting (June 2026), Warsh held rates steady at 3.50–3.75% but delivered a hawkish surprise: 9 of 18 FOMC members now project a 2026 hike and the easing bias was stripped. Polymarket gives 53–54% probability of a Fed rate hike in 2026. Jackson Hole (2026 theme: 'Financial Innovation: Implications for Payments and Policy') is traditionally the venue for policy turn signals. September 16–17 is the most plausible meeting — a Grand Teton announcement would be consistent with historical Fed practice.
💻 Technology
✦ AI
OpenAI released GPT-5.6 (variants Luna, Terra, Sol) on July 9, 2026, calling Sol its 'strongest model ever'. In the competitive AI market, Anthropic faces strong pressure to counter with a flagship Claude update. AI model cycles have compressed to 4–8 months industry-wide. Anthropic has historically released flagship updates at comparable intervals. No direct Polymarket signal; market structure and competitive dynamics support ~79%.
📈 Economy
Miss
✦ AI
Eli Lilly reports on August 5, 2026. The EPS consensus per Hudson Labs is ~$8.89 adjusted Non-GAAP EPS. Eli Lilly has beaten estimates for eight consecutive quarters, driven by explosive growth of Mounjaro (tirzepatide, diabetes/GLP-1) and Zepbound (obesity). The GLP-1 segment grows double-digits and routinely outpaces analyst estimates. No Polymarket market available; assessment based on ~85–90% historical beat rate over the last 8 quarters. Risk: potential supply constraints or price pressure from IRA negotiations.
💻 Technology
Hit
✦ AI
xAI released Grok 3 in February 2025. Leading AI labs (Anthropic, OpenAI, Google) typically ship new generations 9–15 months apart, placing Grok 4 most plausibly in the November 2025–May 2026 window — or if delayed, summer/fall 2026. xAI has recently expanded the Colossus cluster to 200,000 H100 GPUs. Elon Musk has publicly committed to making Grok the world's most intelligent AI. EU AI Act (high-risk obligations from August 2, 2026) may influence timing. No Polymarket/Kalshi market for Grok 4 release found; estimate based on development cadence and public xAI statements. Counterargument: xAI announces releases with little notice — delays to September–October 2026 possible.
🍾 Beverages
✦ AI
Pernod Ricard (Jameson, Absolut, Chivas Regal) recorded an organic net sales decline of -3.0% in FY2025 (fiscal year ending June 30, 2025; reported decline -5.5% including FX; net sales €10,959m). The company itself issued guidance of -3% to -4% organic for FY2026 (Investing.com, July 2026). The midpoint is -3.5%, already exceeding the >3.0% threshold. Persistently weak China demand (cognac/whisky -21% in China, FY2025), US spirits market stagnation and Mexico/tequila normalization continue to weigh. The entire premium spirits segment shows negative trends (cf. Diageo, Brown-Forman, Campari — all open Cassandra predictions with negative outlooks).
💻 Technology
Hit
✦ AI
AMD reports Q2 2026 after market close on August 4. Non-GAAP EPS consensus approx. $1.61, revenue consensus approx. $11.29B (+47% YoY) (TipRanks/Yahoo Finance). AMD's own Q2 revenue guidance of $11.2B already exceeded the analyst consensus of $10.5B — a strong beat signal. New GPU contracts with OpenAI and Meta for 6GW MI450 deployments (first shipments H2 2026) and strong EPYC Zen 6 CPU demand support the outlook. AMD's 'Advancing AI 2026' conference (July 22–23) likely reinforced positive demand signals. AMD has beaten consensus EPS in 7 of the last 8 quarters.
🍾 Beverages
Hit
✦ AI
Diageo publishes preliminary FY2026 annual results on August 6 (fiscal year ending June 30, 2026). H1 FY2026 organic net sales already fell 2.8% YoY — a massive drag. Management last confirmed FY2026 guidance of -2% to -3% organic net sales. The Q3 trading update (Apr–Jun 2026) showed only +0.3% organic growth — far insufficient to offset the H1 deficit. North America / US Spirits remains structurally weak. An organic full-year decline exceeding 1.5% is arithmetically near-certain: even with an excellent Q4, the H1 deficit cannot be compressed below -1.5% for the full year.
📈 Economy
Hit
✦ AI
Shell reports Q2 2026 results on July 30. The adjusted CCS earnings consensus is estimated at approx. USD 5.5–6.0bn, based on the historical quarterly run-rate of ~USD 5.9bn (FY2024 total: ~USD 23.7bn). Key beat drivers: (1) WTI rose to USD 84.42 in July 2026 (+14% over the month) on the US naval blockade — but Q2 billing period is April–June, so average oil prices in Q2 were likely USD 78–82/bbl; (2) integrated gas/LNG benefits from TTF stability (~EUR 58–60/MWh); (3) downstream margins recovering from 2024 weakness. No Polymarket/Kalshi markets found; calibrated on historical beat pattern and oil price trajectory.
💻 Technology
Hit
✦ AI
Polymarket prices the release of a new Google Gemini Pro flagship model by August 31, 2026 at 86% (as of July 22, 2026; volume USD 259,000). By contrast, the odds for a July 25 release were only 2%, concentrating ~84% of probability between July 26 and August 31. Anthropic currently dominates Polymarket's 'best AI model' ranking (July end: 99%), creating strategic urgency for Google to respond. The proprietary estimate is marginally below Polymarket due to recurring release-delay risk in the AI sector.
📈 Economy
Hit
✦ AI
Starbucks is in an operational turnaround under CEO Brian Niccol (since September 2024). The stock hit a new one-year high in July 2026, confirming market confidence in the rebound thesis. The EPS consensus of USD 0.65 for Q3 FY2026 implies +30% YoY growth (prior year: USD 0.50). Companies in CEO-driven turnaround phases historically beat analyst consensus at above-average rates. Revenue consensus: USD 9.20 billion. Starbucks beat consensus in Q1 and Q2 FY2026.
📈 Economy
Hit
✦ AI
Sanofi publishes Q2-2026 results on July 30. Business EPS consensus ~€1.88; revenue consensus ~€11.39B (Chartmill/TipRanks, July 2026). In Q1 2026, Sanofi delivered double-digit sales and Business EPS growth, driven by Dupixent (leading biologic for atopic dermatitis/asthma, quarterly revenue >€4B) and Beyfortus (RSV infant protection, seasonally lower in Q2). Annual guidance: high single-digit sales growth, Business EPS slightly faster than sales. No prediction market found.
📈 Economy
Hit
✦ AI
Novo Nordisk reports H1-2026 results on August 5 at 07:30 CEST. EPS consensus is $5.31; revenue consensus ~DKK 73.06B (Unusual Whales/MarketBeat, July 2026). Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 1.0/2.0 mg) dominate the globally growing GLP-1 market. Novo has beaten EPS consensus in more than six consecutive quarters. Risks: US IRA negotiations on GLP-1 reimbursement, competition from Eli Lilly's tirzepatide, China price pressure. No specific prediction market.